COVID-19: Viral Infection, Endotheliopathy and the Immuno-Inflammatory Response. . . Is It Time to Consider a Standard (Non-immunized) Plasma Therapy Approach to Maintain Homeostasis?
Abstract
Severe novel Coronavirus Disease 2019 (COVID-19) is characterized by severe pneumonia, requiring hospitalization in Intensive Care Units (ICUs). Respiratory and multi-organ failure most often occur secondarily (median 10 days after the onset of symptoms)[1].Transient viremia is documented in severe forms [2] but death can occur even after viral clearance. Thromboembolic complications, including deep vein thrombosis and pulmonary embolism, are also reported [3]. Finally, with skin lesions similar to vasculitis or vasomotor disorders COVID-19 is described as an infectious disease with vascular manifestations [4]. SARS-COV-2 infection relies on direct endothelial dysfunction by downregulation of ACE2 and studies ofCOVID-19 pathophysiology highlighted inflammatory and vascular mechanisms [5]. All these may be treated by new therapeutic approaches, but not necessarily with new drugs. Here, we discuss these mechanisms and how therapeutic non-immunized plasma(i.e. not specifically collected in COVID-19 convalescent donors)could be integrated into treatment protocols.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 02, 2022
- Accession Number
- AD1174236
Entities
People
- Andre P Cap
- Anne Sailliol
- Emilie Javelle
- Frederique Dufour-gaume
- Nicolas J. Prat